These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 37139988)

  • 21. A Rare Case Report of Metastatic Urothelial Carcinoma to Skull with Significant Reossification after Pembrolizumab.
    Liu YH; Chou MH; Meng E; Kao CC
    Medicina (Kaunas); 2021 Sep; 57(9):. PubMed ID: 34577910
    [No Abstract]   [Full Text] [Related]  

  • 22. Impact of the objective response to and number of cycles of platinum-based first-line chemotherapy for metastatic urothelial carcinoma on overall survival of patients treated with pembrolizumab.
    Kato M; Kobayashi T; Matsui Y; Ito K; Hikami K; Yamada T; Ogawa K; Nakamura K; Sassa N; Yokomizo A; Abe T; Tsuchihashi K; Tatarano S; Inokuchi J; Tomida R; Fujiwara M; Takahashi A; Matsumoto K; Shimizu K; Araki H; Kurahashi R; Ozaki Y; Tashiro Y; Uegaki M; Kojima T; Uchida J; Ogawa O; Nishiyama H; Kitamura H;
    Int J Urol; 2021 Dec; 28(12):1261-1267. PubMed ID: 34545627
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and Tolerability of Tremelimumab in Locally Advanced or Metastatic Urothelial Carcinoma Patients Who Have Failed First-Line Platinum-Based Chemotherapy.
    Sharma P; Sohn J; Shin SJ; Oh DY; Keam B; Lee HJ; Gizzi M; Kalinka E; de Vos FYFL; Ruscica D; Ferro S; Xiao F; Baverel P; Chen CC; Asubonteng K; Morsli N; Dirix L
    Clin Cancer Res; 2020 Jan; 26(1):61-70. PubMed ID: 31801732
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical practice pattern in patients with advanced urothelial cancer who had progressed on pembrolizumab in the pre-enfortumab vedotin era.
    Kita Y; Ito K; Sano T; Hashimoto K; Mochizuki T; Shiraishi Y; Araki H; Fujiwara M; Kanamaru S; Takahashi T; Hishiki K; Okada T; Ogawa K; Ito M; Kojima T; Nishiyama N; Matsui Y; Nishiyama H; Kitamura H; Kobayashi T
    Int J Urol; 2022 Jul; 29(7):647-655. PubMed ID: 35304776
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status.
    Grivas P; Plimack ER; Balar AV; Castellano D; O'Donnell PH; Bellmunt J; Powles T; Hahn NM; de Wit R; Bajorin DF; Ellison MC; Frenkl TL; Godwin JL; Vuky J
    Eur Urol Oncol; 2020 Jun; 3(3):351-359. PubMed ID: 32423837
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Complete Response With Immunotherapy: A Case of Metastatic Bladder Cancer.
    Singh B; Kaur P; Gupta S; Guragai N; Maroules M
    J Investig Med High Impact Case Rep; 2021; 9():23247096211035603. PubMed ID: 34308703
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Squamous differentiation is a potential biomarker predicting tumor progression in patients treated with pembrolizumab for urothelial carcinoma.
    Miyama Y; Morikawa T; Miyakawa J; Koyama Y; Kawai T; Kume H; Ushiku T
    Pathol Res Pract; 2021 Mar; 219():153364. PubMed ID: 33610951
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sex hormones influence survival of patients with metastatic urothelial carcinoma undergoing immune checkpoint therapy.
    Lindner AK; Lackner F; Tymoszuk P; Barth DA; Seeber A; Kocher F; Toth B; Hochleitner M; Pichler M; Pichler R
    Biol Sex Differ; 2023 Jun; 14(1):38. PubMed ID: 37277835
    [TBL] [Abstract][Full Text] [Related]  

  • 29. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.
    Balar AV; Castellano D; O'Donnell PH; Grivas P; Vuky J; Powles T; Plimack ER; Hahn NM; de Wit R; Pang L; Savage MJ; Perini RF; Keefe SM; Bajorin D; Bellmunt J
    Lancet Oncol; 2017 Nov; 18(11):1483-1492. PubMed ID: 28967485
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of PD-L1 testing on the cost-effectiveness and budget impact of pembrolizumab for advanced urothelial carcinoma of the bladder in the United States.
    Criss SD; Weaver DT; Sheehan DF; Lee RJ; Pandharipande PV; Kong CY
    Urol Oncol; 2019 Mar; 37(3):180.e11-180.e18. PubMed ID: 30528699
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study.
    Plimack ER; Bellmunt J; Gupta S; Berger R; Chow LQ; Juco J; Lunceford J; Saraf S; Perini RF; O'Donnell PH
    Lancet Oncol; 2017 Feb; 18(2):212-220. PubMed ID: 28081914
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of Histological Variants on Clinical Responses to Pembrolizumab in Patients With Metastatic Urothelial Cancer.
    Inoue S; Sassa N; Kawanishi H; Yuguchi Y; Suzuki T; Nagayama J; Matsui H; Miyata Y; Soeda Y; Tochigi K; Yamauchi Y; Maeda M; Kobayashi I; Hattori R; Matsukawa Y; Kato M
    Anticancer Res; 2022 Jul; 42(7):3627-3636. PubMed ID: 35790259
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical Benefit of Pembrolizumab in Advanced Urothelial Cancer Patients in Real-Life Setting: An Efficacy and Safety Monocentric Study.
    Dang E; Vallée A; Lepage-Seydoux C; Sejean K; Bonan B; Abraham C; Beuzeboc P; Ratta R
    Curr Oncol; 2022 Feb; 29(2):945-955. PubMed ID: 35200579
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preexisting Autoantibodies and Immune Related Adverse Events in Metastatic Urothelial Carcinoma Patients Treated by Pembrolizumab.
    Castel-Ajgal Z; Goulvestre C; Zaibet S; Arrondeau J; Bretagne M; Peyromaure M; Batteux F; Alexandre J; Goldwasser F; Huillard O
    Clin Genitourin Cancer; 2022 Oct; 20(5):e362-e368. PubMed ID: 35577731
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
    André T; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt C; Smith D; Garcia-Carbonero R; Benavides M; Gibbs P; de la Fouchardiere C; Rivera F; Elez E; Bendell J; Le DT; Yoshino T; Van Cutsem E; Yang P; Farooqui MZH; Marinello P; Diaz LA;
    N Engl J Med; 2020 Dec; 383(23):2207-2218. PubMed ID: 33264544
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The pretreatment neutrophil-to-lymphocyte ratio is a novel biomarker for predicting clinical responses to pembrolizumab in platinum-resistant metastatic urothelial carcinoma patients.
    Ogihara K; Kikuchi E; Shigeta K; Okabe T; Hattori S; Yamashita R; Yoshimine S; Shirotake S; Nakazawa R; Matsumoto K; Mizuno R; Hara S; Oyama M; Masuda T; Niwakawa M; Oya M
    Urol Oncol; 2020 Jun; 38(6):602.e1-602.e10. PubMed ID: 32139290
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [A Case of Metastatic Urothelial Carcinoma with Pseudoprogression of Liver Metastasis during the Treatment with Pembrolizumab].
    Masuda H; Kato M; Yoshiuchi H; Yukimatsu N; Hirayama Y; Otoshi T; Yamasaki T; Kuratsukuri K; Uchida J
    Hinyokika Kiyo; 2022 Apr; 68(4):117-121. PubMed ID: 35613900
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Atezolizumab for the treatment of advanced recurrent basal cell carcinoma and urothelial carcinoma of bladder: a case report.
    Küronya Z; Danyi T; Balatoni T; Liszkay G; Tóth E; Biró K; Géczi L
    J Med Case Rep; 2022 Oct; 16(1):396. PubMed ID: 36316780
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Complete and long-lasting response to immunotherapy: A case report of urothelial cancer.
    Silva DJ; Mesquita A
    Medicine (Baltimore); 2022 Jun; 101(24):e28940. PubMed ID: 35713423
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Excellent Response to Atezolizumab After Clinically Defined Hyperprogression Upon Previous Treatment With Pembrolizumab in Metastatic Triple-Negative Breast Cancer: A Case Report and Review of the Literature.
    Feng D; Guan Y; Liu M; He S; Zhao W; Yin B; Liang J; Li Y; Wang J
    Front Immunol; 2021; 12():608292. PubMed ID: 34135884
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.